Abhinav Vayal-Veettil

Race and the neoadjuvant-to-adjuvant pembrolizumab transition for early-stage triple-negative breast cancer in the KEYNOTE-522 era: A TriNetX US Collaborative Network analysis.

238 Background: Pembrolizumab plus chemotherapy is standard neoadjuvant therapy for high-risk early-stage triple-negative breast cancer (TNBC) per KEYNOTE-522. Prior real-world studies have documented Black-White disparities in initial KEYNOTE-522 receipt and regimen tolerability, but the discrete neoadjuvant-t...